VectivBio Competitors

VectivBio (NASDAQ:VECT) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for VectivBio and Immunocore, as reported by MarketBeat.com.

VectivBio presently has a consensus target price of $23.6667, suggesting a potential upside of 75.57%. Immunocore has a consensus target price of $54.3333, suggesting a potential upside of 34.66%. Given VectivBio's stronger consensus rating and higher possible upside, equities analysts plainly believe VectivBio is more favorable than Immunocore.

Profitability

This table compares VectivBio and Immunocore's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares VectivBio and Immunocore's gross revenue, earnings per share (EPS) and valuation.

Summary

VectivBio beats Immunocore on 3 of the 3 factors compared between the two stocks.

VectivBio (NASDAQ:VECT) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Earnings & Valuation

This table compares VectivBio and BioAtla's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares VectivBio and BioAtla's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for VectivBio and BioAtla, as reported by MarketBeat.com.

VectivBio presently has a consensus target price of $23.6667, suggesting a potential upside of 75.57%. BioAtla has a consensus target price of $62.75, suggesting a potential upside of 33.03%. Given VectivBio's higher possible upside, equities analysts plainly believe VectivBio is more favorable than BioAtla.

Summary

VectivBio beats BioAtla on 1 of the 1 factors compared between the two stocks.

VectivBio (NASDAQ:VECT) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares VectivBio and Edgewise Therapeutics' revenue, earnings per share and valuation.

Profitability

This table compares VectivBio and Edgewise Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations for VectivBio and Edgewise Therapeutics, as provided by MarketBeat.com.

VectivBio currently has a consensus target price of $23.6667, suggesting a potential upside of 75.57%. Edgewise Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 27.61%. Given VectivBio's stronger consensus rating and higher probable upside, analysts plainly believe VectivBio is more favorable than Edgewise Therapeutics.

Summary

VectivBio beats Edgewise Therapeutics on 3 of the 3 factors compared between the two stocks.

VectivBio (NASDAQ:VECT) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares VectivBio and Cullinan Oncology's revenue, earnings per share and valuation.

Profitability

This table compares VectivBio and Cullinan Oncology's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations for VectivBio and Cullinan Oncology, as provided by MarketBeat.com.

VectivBio currently has a consensus target price of $23.6667, suggesting a potential upside of 75.57%. Cullinan Oncology has a consensus target price of $48.75, suggesting a potential upside of 70.10%. Given VectivBio's higher probable upside, analysts plainly believe VectivBio is more favorable than Cullinan Oncology.

Summary

VectivBio beats Cullinan Oncology on 1 of the 1 factors compared between the two stocks.

VectivBio (NASDAQ:VECT) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares VectivBio and Nurix Therapeutics' revenue, earnings per share and valuation.

Profitability

This table compares VectivBio and Nurix Therapeutics' net margins, return on equity and return on assets.

Institutional & Insider Ownership

82.0% of Nurix Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for VectivBio and Nurix Therapeutics, as provided by MarketBeat.com.

VectivBio currently has a consensus target price of $23.6667, suggesting a potential upside of 75.57%. Nurix Therapeutics has a consensus target price of $46.00, suggesting a potential upside of 69.18%. Given VectivBio's higher probable upside, analysts plainly believe VectivBio is more favorable than Nurix Therapeutics.

Summary

Nurix Therapeutics beats VectivBio on 2 of the 3 factors compared between the two stocks.

VectivBio (NASDAQ:VECT) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares VectivBio and Kinnate Biopharma's revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current recommendations for VectivBio and Kinnate Biopharma, as provided by MarketBeat.com.

VectivBio currently has a consensus target price of $23.6667, suggesting a potential upside of 75.57%. Kinnate Biopharma has a consensus target price of $52.00, suggesting a potential upside of 121.75%. Given Kinnate Biopharma's higher probable upside, analysts plainly believe Kinnate Biopharma is more favorable than VectivBio.

Profitability

This table compares VectivBio and Kinnate Biopharma's net margins, return on equity and return on assets.

Summary

Kinnate Biopharma beats VectivBio on 1 of the 1 factors compared between the two stocks.